Recordati Industria Chimica E Farmaceutica S.p.A.(OTC) RCDTF

Recordati S.p.A. is a global pharmaceutical company headquartered in Milan, Italy, specializing in the research, development, production, and sale of pharmaceuticals. The company operates in various segments, including Specialty and Primary Care, and Rare Diseases, providing innovative treatments for a range of medical conditions.

Products and Services

• Specialty pharmaceuticals for rare diseases and complex conditions
• Primary care medications for chronic diseases like hypertension
• Innovative treatments for various therapeutic areas, including oncology and endocrinology

Growth Outlook

• Revenue increased to €716 million in Q1 2026, reflecting strong demand
• Net income rose to €153 million in Q1 2026, showcasing profitability
• Continued investment in R&D supports future product pipeline expansion

Financial Highlights

• Trailing twelve months (TTM) revenue of €2.7 billion, indicating robust performance
• Net profit margin of 17.8% TTM, demonstrating effective cost management
• Dividend yield of 2.61% TTM, appealing for income-focused investors

Recordati S.p.A. has established itself as a key player in the pharmaceutical industry, with a diverse portfolio of products addressing critical health needs. The company's commitment to research and development is evident in its innovative therapies, particularly in rare diseases, which are often underserved in the market. Recent financial performance highlights a strong upward trend in revenue and profitability, positioning Recordati favorably for future growth. The company's strategic focus on expanding its product offerings and entering new markets further enhances its growth potential, making it an attractive option for investors interested in the healthcare sector.